Dianthus Therapeutics, Inc. (DNTH)
NASDAQ: DNTH · Real-Time Price · USD
27.75
-0.37 (-1.32%)
Oct 29, 2024, 4:00 PM EDT - Market closed

Dianthus Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2023 FY 2022 FY 2021
Period Ending
Jun '24 Dec '23 Dec '22 Dec '21
Revenue
4.122.836.421.48
Revenue Growth (YoY)
8.57%-55.96%334.76%-
Gross Profit
4.122.836.421.48
Selling, General & Admin
24.9918.166.741.96
Research & Development
47.8932.8429.3812.61
Operating Expenses
72.885136.1214.56
Operating Income
-68.76-48.17-29.71-13.09
Interest & Investment Income
12.44.761.150
Currency Exchange Gain (Loss)
-0.09-0.090.14-0.03
Other Non Operating Income (Expenses)
-0.23-0.06-0.05-
Pretax Income
-56.68-43.56-28.48-13.11
Net Income
-56.68-43.56-28.48-13.11
Net Income to Common
-56.68-43.56-28.48-13.11
Shares Outstanding (Basic)
21514
Shares Outstanding (Diluted)
21514
Shares Change (YoY)
413.54%489.48%-78.18%-
EPS (Basic)
-2.75-8.45-32.57-3.27
EPS (Diluted)
-2.75-8.45-32.57-3.27
Free Cash Flow
-51.44-36.97-29.21-9.94
Free Cash Flow Per Share
-2.50-7.17-33.41-2.48
Gross Margin
100.00%100.00%100.00%100.00%
Operating Margin
-1669.82%-1704.67%-462.91%-886.59%
Profit Margin
-1376.42%-1541.22%-443.76%-888.14%
Free Cash Flow Margin
-1249.13%-1308.24%-455.18%-673.24%
EBITDA
-68.68-48.11-29.68-
D&A For EBITDA
0.080.070.03-
EBIT
-68.76-48.17-29.71-13.09
Source: S&P Capital IQ. Standard template. Financial Sources.